Houghton PJ - Search Results

1

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

Huang S, Houghton PJ. Huang S, et al. Among authors: houghton pj. Curr Opin Investig Drugs. 2002 Feb;3(2):295-304. Curr Opin Investig Drugs. 2002. PMID: 12020063 Review.

2

Rhabdomyosarcoma. From the laboratory to the clinic.

Houghton PJ, Shapiro DN, Houghton JA. Houghton PJ, et al. Among authors: houghton ja. Pediatr Clin North Am. 1991 Apr;38(2):349-64. doi: 10.1016/s0031-3955(16)38081-6. Pediatr Clin North Am. 1991. PMID: 2006081 Review.

3

Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.

Houghton PJ, Houghton JA, Hazelton BJ, Radparvar S. Houghton PJ, et al. Among authors: houghton ja. Invest New Drugs. 1989 Apr;7(1):59-69. doi: 10.1007/BF00178192. Invest New Drugs. 1989. PMID: 2661484 Review.

4

Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Dilling MB, et al. Among authors: houghton pj. Cancer Res. 1994 Feb 15;54(4):903-7. Cancer Res. 1994. PMID: 7508822

5

Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.

Houghton PJ, Cheshire PJ, Hallman JC 3rd, Gross JL, McRipley RJ, Sun JH, Behrens CH, Dexter DL, Houghton JA. Houghton PJ, et al. Among authors: houghton ja. Cancer Chemother Pharmacol. 1994;33(4):265-72. doi: 10.1007/BF00685898. Cancer Chemother Pharmacol. 1994. PMID: 8281618

6

Topoisomerase I interactive drugs in children with cancer.

Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB. Stewart CF, et al. Among authors: houghton pj. Invest New Drugs. 1996;14(1):37-47. doi: 10.1007/BF00173681. Invest New Drugs. 1996. PMID: 8880392 Review.

7

Antitumor diarylsulfonylureas: novel agents with unfulfilled promise.

Houghton PJ, Houghton JA. Houghton PJ, et al. Among authors: houghton ja. Invest New Drugs. 1996;14(3):271-80. doi: 10.1007/BF00194530. Invest New Drugs. 1996. PMID: 8958182 Review.

8

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin.

Brunn GJ, Hudson CC, Sekulić A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC Jr, Abraham RT. Brunn GJ, et al. Among authors: houghton pj. Science. 1997 Jul 4;277(5322):99-101. doi: 10.1126/science.277.5322.99. Science. 1997. PMID: 9204908

9

Animal models for studying the action of topoisomerase I targeted drugs.

Thompson J, Stewart CF, Houghton PJ. Thompson J, et al. Among authors: houghton pj. Biochim Biophys Acta. 1998 Oct 1;1400(1-3):301-19. doi: 10.1016/s0167-4781(98)00143-2. Biochim Biophys Acta. 1998. PMID: 9748639 Review.

10

Studies on the mechanism of resistance to rapamycin in human cancer cells.

Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC Jr, Houghton PJ. Hosoi H, et al. Among authors: houghton pj. Mol Pharmacol. 1998 Nov;54(5):815-24. doi: 10.1124/mol.54.5.815. Mol Pharmacol. 1998. PMID: 9804616

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

589 results

Search Page